What does Palatin Technologies do and what are its main business segments?

What is Palatin Technologies's gross profit margin?

What factors drove the changes in Palatin Technologies's revenue and profit?

What were the key takeaways from Palatin Technologies’s earnings call?

What is the market's earnings forecast for Palatin Technologies next quarter?

What were the key takeaways from Palatin Technologies's earnings call?

Did Palatin Technologies beat or miss consensus estimates last quarter?

What is Palatin Technologies's latest dividend and current dividend yield?

- **$18.2M Public Offering Success**: Restored NYSE listing and strengthened balance sheet for pipeline advancement.
- **Revenue Growth**: $116,000 from Boehringer collaboration, up from $0 prior year.
- **Pipeline Milestones**: PL-7737 IND submission and Phase I trial in Q2 2026; next-gen peptide IND in H2 2026.
- **Strategic Focus**: Rare obesity disorders (HO, PWS) with differentiated MC4R agonists targeting reduced side effects.
- **Cash Runway**: $14.5M as of Dec 2025, extending into 2027.
- **Q&A Highlights**: Confidence in PL-7737's safety profile; potential for MC4R/GLP-1 combination therapies.

**【CEO Opening Remarks】**
- Reported Q2 2026 financial results, highlighting progress in melanocortin-4 receptor (MC4R) based obesity pipeline.
- Emphasized strategic focus on rare neuroendocrine obesity disorders (e.g., hypothalamic obesity, Prader-Willi syndrome) and advancing lead programs PL-7737 and next-gen peptide.
- Announced sublicensing of PL9643 to Altanispac Labs, providing $3.8M upfront consideration and sharpening focus on core obesity programs.

**【CFO Financial Commentary】**
- Completed $18.2M public offering in November 2025, restoring NYSE American listing and strengthening balance sheet.
- Q2 2026 revenue: $116,000 (cost reimbursements from Boehringer Ingelheim collaboration), up from $0 in prior year.
- Operating expenses: $7.4M (vs. $2.6M prior year), driven by pipeline advancement and one-time costs.
- Cash position: $14.5M as of Dec 31, 2025, with cash runway extending beyond Q1 2027.
- Net loss: $7.3M ($2.86/share) due to higher R&D expenses and absence of prior year divestiture gain.

**【CEO Pipeline Update】**
- PL-7737: IND submission and Phase I trial targeting Q2 2026; designed to minimize GI side effects and hyperpigmentation.
- Next-gen peptide: IND submission planned for H2 2026; weekly dosing for long-term efficacy.
- Preclinical data supports MC4R agonist/GLP-1 combination potential for enhanced efficacy.
- Clinical trials to focus on rare obesity indications with high unmet need.

**【Q&A Highlights】**
- **Product Differentiation**: PL-7737 designed for MC4R selectivity to reduce hyperpigmentation; slow absorption to mitigate GI side effects.
- **Clinical Trial Design**: Phase I SAD/MAD studies in healthy obese patients will assess safety and efficacy signals; Phase II targeting rare obesity populations.
- **Financial Outlook**: Q3 2026 OpEx expected to decrease by ~$2.5M due to one-time expenses in Q2.
- **Combination Therapy**: Exploring MC4R agonist/GLP-1 combinations for severe obesity cases, with preclinical data supporting synergy.


Palatin Technologies, Inc. (PTN) Q2 2026 Earnings Call Transcript

- **Strategic Milestones Achieved**: $2.3M upfront and $6.5M milestone from BI, $16.9M public offering, and NYSE relisting.
- **Pipeline Progress**: PL7737 IND filing Q2 2026, long-acting peptides entering IND studies Q2 2026, and $307M potential in retinal disease collaboration.
- **Financial Stability**: Net income of $4.7M, 59% expense reduction, and extended cash runway beyond 2026.
- **Market Differentiation**: Next-gen MC4R agonists with reduced side effects and first-in-class positioning in obesity treatment.

**【Management Opening Remarks】**
- **Boehringer Ingelheim Collaboration**: Received upfront payment of $2.3 million and a $6.5 million milestone, with potential for up to $307 million in future milestones and royalties.
- **Public Offering**: Raised $16.9 million (gross) through an 18.2 million share offering, including Series J and K warrants. Series J warrants exercisable at $6.50 if FDA accepts IND by mid-2026; Series K warrants at $8.12 expiring in 2030.
- **NYSE Compliance**: Resumed trading on NYSE American under symbol PTN after regaining compliance.

**【CEO Commentary】**
- **Obesity Pipeline Focus**: 
  - **PL7737**: Oral MC4R agonist with reduced MC1R activity to minimize hyperpigmentation. IND filing expected Q2 2026, with Phase 1 data in Q4 2026.
  - **Long-acting Peptides**: Target weekly or bi-weekly dosing; IND-enabling studies to begin Q2 2026, with first-in-human studies in Q4 2026.
- **Strategic Licensing**: Advanced programs (e.g., PL9643 for dry eye, PL8177 for ulcerative colitis) available for licensing, with BI collaboration as a validation of melanocortin system potential.

**【CFO Financial Commentary】**
- **Q1 2026 Financials**: 
  - Revenue: $8.8 million (vs. $0 prior year) from BI collaboration.
  - Net Income: $4.7 million (vs. $7.8 million loss prior year).
  - Operating Expenses: $4.2 million (59% YoY decline) due to reduced non-core R&D spending.
  - Cash Position: $1.3 million as of Sep 30, 2025, but post-offering, cash runway extended beyond Q4 2026.
- **Liquidity**: Public offering proceeds and expected Series J warrant exercises provide financial stability for obesity program development.

**【Q&A Highlights】**
- **Pipeline Differentiation**: PL7773 and peptides designed for flat PK profiles to maintain efficacy without GI side effects; >100,000-fold MC4R/MC1R selectivity reduces pigmentation risk.
- **Competitive Positioning**: Confident in multi-billion-dollar obesity market potential; focus on first-in-class MC4R-selective compounds.
- **Future Collaborations**: Expect $14.5 million in near-term milestones from BI within 12 months, with active business development for other melanocortin programs.

Palatin Technologies Inc (PTN) Q1 2026 Earnings Call Transcript

- **Financial Stability**: Net loss reduced 69% YoY to $2.4M; $3.4M cash on hand supports 2025 operations.
- **Obesity Pipeline Momentum**: Two new MCR4 receptor programs set for IND in 2025; Phase II BMT-801 data imminent.
- **Strategic Focus**: Targeting $100B+ obesity market with differentiated MCR4 agonists; exploring rare disease opportunities.
- **Partnership Opportunities**: Multiple programs (obesity, UC, kidney disease) in active partner discussions.

**【CFO Financial Update】**
- **Revenue Decline**: Q2 2024 product revenue was $2 million (down from $4.3 million in Q2 2023) due to the sale of Vyleesi rights in 2023.
- **Operating Expenses**: Total expenses were $2.6 million (net of a $2.5M gain on Vyleesi sale), up 189% YoY due to reduced sale-related gains.
- **Net Loss**: Improved to $2.4 million (from $7.8 million YoY) driven by reduced warrant liability adjustments.
- **Cash Position**: $3.4 million as of Dec 31, 2024 (excluding $4.3M equity raise in Feb 2025), with active funding discussions.

**【CEO Operational Highlights】**
- **BMT-801 Study**: Phase II trial combining bremelanotide with tirzepatide for obesity completed; topline data expected late Dec 2024.
- **Obesity Portfolio**: Two new MCR4 receptor programs (long-acting peptide & oral small molecule) advancing to IND in 2025.
- **Ulcerative Colitis**: PL8177 Phase II data release expected Q1 2025; partner discussions ongoing.
- **Kidney Disease**: Bremelanotide study (BREAKOUT) showed 71% proteinuria reduction; partner outreach initiated.
- **Strategic Focus**: Prioritizing MCR4 receptor agonists for obesity, targeting $100B+ market potential.

**【Q&A Key Points】**
- **BMT-801 Benchmarking**: Seeking >4% weight loss vs. tirzepatide alone; focus on maintenance phase weight retention.
- **Rare Disease Potential**: Exploring MCR4 agonists for Prader-Willi Syndrome and other syndromic obesity indications.
- **2025 Outlook**: Multiple programs (obesity, UC, kidney disease) poised for partnership discussions and clinical advancement.

Palatin (PTN)-13 Feb 25-2025 Q2 Earnings call transcript

Palatin (PTN)-14 Nov 24-2025 Q1 Earnings call transcript

Palatin (PTN)-15 May 24-2024 Q3 Earnings call transcript

- **Vyleesi Momentum**: 7 straight quarters of double-digit growth, with net revenue exceeding operating expenses.
- **Dry Eye Breakthrough**: MELODY-1 Phase III study on track for year-end top-line data, targeting superior efficacy and tolerability.
- **Obesity Innovation**: GLP-1/bremelanotide combo study to launch Q1 2024, addressing weight loss maintenance and side effects.
- **Financial Resilience**: $5.5M cash on hand, with $4.5M raised in October, supporting operations into H1 2024.

**【CEO Summary Section】**
- Vyleesi achieved 7 consecutive quarters of double-digit growth, with net product revenue exceeding quarterly operating expenses.
- Phase III MELODY-1 study for dry eye disease (DED) is fully enrolled, with top-line data expected by year-end and full results in Q1 2024.
- New clinical programs include a Phase II study combining bremelanotide with GLP-1 agonists for obesity and erectile dysfunction (ED) patients unresponsive to PD-5 inhibitors.
- Cash position as of September 30, 2023, was $5.5 million, plus $1.3 million in accounts receivable, with $4.5 million raised in a registered direct offering in October 2023.

**【CFO Financial Commentary】**
- Gross product sales for Vyleesi: $4.6 million (Q1 2024) vs. $2.3 million (Q1 2023), +100% YoY.
- Net product revenue: $2.1 million (Q1 2024) vs. $1.0 million (Q1 2023), +142% YoY.
- Total operating expenses: $8.2 million (Q1 2024) vs. $9.6 million (Q1 2023), -14% YoY due to reduced monocortin program costs.
- Net loss: $5.9 million (Q1 2024) vs. $8.3 million (Q1 2023), -29% YoY.
- Cash used in operations: $5.9 million (Q1 2024) vs. $8.6 million (Q1 2023), -31% YoY.

**【Q&A Key Highlights】**
- **MELODY-1 Data**: Primary endpoints include inferior corneal staining and ocular pain; full dataset to be released in Q1 2024. Secondary endpoints include tear breakup time and dryness symptoms.
- **GLP-1 Combination Study**: Targeting obese patients (BMI >35) on tirzepatide, with focus on weight loss maintenance and tolerability. Preclinical data shows melanocortin agonists can enhance weight loss without increasing GLP-1 dose.
- **Out-Licensing Progress**: Vyleesi discussions with women's health companies advanced, with expectation of transaction in the near term.
- **Breakout Study**: Phase II open-label study in diabetic kidney disease patients; data expected in Q1 2024. Bremelanotide used as proof of concept for broader melanocortin receptor agonist pipeline.

Actual					-37.5	-37.5	-50	-67	-43	-6.5	-45.5	-24	-28	-26.5	-19.5	-6	-9	4.26	-2.86
Forecast					-30.2265	-41.7294	-38.0414	-39.6667	-54	-28.8333	-26.3333	-20.25	-10.1667	-22.3333	-25.5	-21	-8.5		-2.3533
Surprise	0.00%	0.00%	0.00%	0.00%	-24.06%	+10.14%	-31.44%	-68.91%	+20.37%	+77.46%	-72.79%	-18.52%	-175.41%	-18.66%	+23.53%	+71.43%	-5.88%	0.00%	-21.53%

Actual	--	--	--	--	0	159.48K	322.14K	770.74K	869.65K	1.03M	1.76M	2.11M	2.03M	0	0	0	--	8.85M	25.00K
Forecast	--	--	--	--	0	51.67K	126.00K	193.33K	747.00K	1.58M	1.32M	5.60M	6.29M	121.00K	0	0	0	--	25.00K
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	+208.67%	+155.67%	+298.66%	+16.42%	-35.19%	+33.65%	-62.38%	-67.67%	-100.00%	0.00%	0.00%	0.00%	0.00%	0.00%

PTN

PTN fundamentals

PTN Q2 2026 Earnings

Earnings Call

You can ask Aime

PTN

PTN fundamentals

PTN Q2 2026 Earnings

Earnings Call

PTN Earnings Call Summary for Q2/202611:00 AM on Feb 17, 2026

PTN Earnings Call Summary for Q1/202611:00 AM on Nov 13, 2025

PTN Earnings Call Summary for Q3/2025 Apr 7, 2026

PTN Earnings Call Summary for Q2/202511:00 AM on Feb 13, 2025

PTN Earnings Call Summary for Q1/202511:00 AM on Nov 14, 2024

You can ask Aime